Zobrazeno 1 - 10
of 222
pro vyhledávání: '"DAVID B. VOLKIN"'
Autor:
Prashant Kumar, Atsushi Hamana, Christopher Bird, Brandy Dotson, Soraia Saleh-Birdjandi, David B. Volkin, Sangeeta B. Joshi
Publikováno v:
Vaccines, Vol 12, Iss 10, p 1102 (2024)
In this work, we describe compatibility assessments of a recombinant, trivalent non-replicating rotavirus vaccine (t-NRRV) candidate with a mock trivalent Sabin inactivated polio vaccine (t-sIPV). Both t-sIPV and t-NRRV are incompatible with thimeros
Externí odkaz:
https://doaj.org/article/fc336fd9ccac4b5c8867db14bbbe2c86
Autor:
Prashant Kumar, Michael Wang, Ozan S. Kumru, John M. Hickey, Julio Sanmiguel, Nerea Zabaleta, Luk H. Vandenberghe, Sangeeta B. Joshi, David B. Volkin
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 30, Iss , Pp 103-121 (2023)
Recombinant adeno-associated viruses (rAAVs) are a preferred vector system in clinical gene transfer. A fundamental challenge to formulate and deliver rAAVs as stable and efficacious vaccines is to elucidate interrelationships between the vector’s
Externí odkaz:
https://doaj.org/article/c0cdad5aefc247faaa90ba08588e0e25
Autor:
Payton A.-B. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, Prabhu S. Arunachalam, Mengyun Hu, Ozan S. Kumru, Mary Kate Morris, Jane Fontenot, Lisa Shirreff, Jonathan Do, Ya-Chen Cheng, Gayathri Vasudevan, Mark B. Feinberg, Francois J. Villinger, Carl Hanson, Sangeeta B. Joshi, David B. Volkin, Bali Pulendran, Peter S. Kim
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, w
Externí odkaz:
https://doaj.org/article/4b2711e833a84864a890be327d293be9
Autor:
Prashant Kumar, David A. Holland, Kathryn Secrist, Poorva Taskar, Brandy Dotson, Soraia Saleh-Birdjandi, Yetunde Adewunmi, Jennifer Doering, Nicholas J. Mantis, David B. Volkin, Sangeeta B. Joshi
Publikováno v:
Vaccines, Vol 12, Iss 6, p 609 (2024)
Introducing new recombinant protein antigens to existing pediatric combination vaccines is important in improving coverage and affordability, especially in low- and middle-income countries (LMICs). This case-study highlights the analytical and formul
Externí odkaz:
https://doaj.org/article/e3e10b42d9024a5b9e6b93771d69b2c2
Autor:
Ria T. Caringal, John M. Hickey, Nitya Sharma, Kaushal Jerajani, Oluwadara Bewaji, Sarah Brendle, Neil Christensen, Saurabh Batwal, Mustafa Mahedvi, Harish Rao, Vikas Dogar, Rahul Chandrasekharan, Umesh Shaligram, Sangeeta B. Joshi, David B. Volkin
Publikováno v:
Vaccines, Vol 12, Iss 6, p 580 (2024)
During the multi-dose formulation development of recombinant vaccine candidates, protein antigens can be destabilized by antimicrobial preservatives (APs). The degradation mechanisms are often poorly understood since available analytical tools are li
Externí odkaz:
https://doaj.org/article/bba59822ec044a848e29864c5e328c6a
Autor:
Ozan S. Kumru, Sakshi Bajoria, Kawaljit Kaur, John M. Hickey, Greta Van Slyke, Jennifer Doering, Katherine Berman, Charles Richardson, Hans Lien, Harry Kleanthous, Nicholas J. Mantis, Sangeeta B. Joshi, David B. Volkin
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
ABSTRACTSecond-generation COVID-19 vaccines with improved immunogenicity (e.g., breadth, duration) and availability (e.g., lower costs, refrigerator stable) are needed to enhance global coverage. In this work, we formulated a clinical-stage SARS-CoV-
Externí odkaz:
https://doaj.org/article/158fc546f0eb4b9a9cde3509161cd3e9
Autor:
Payton A.-B. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, Prabhu S. Arunachalam, Mengyun Hu, Ozan S. Kumru, Mary Kate Morris, Jane Fontenot, Lisa Shirreff, Jonathan Do, Ya-Chen Cheng, Gayathri Vasudevan, Mark B. Feinberg, Francois J. Villinger, Carl Hanson, Sangeeta B. Joshi, David B. Volkin, Bali Pulendran, Peter S. Kim
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/dbf7e69ac4e540d2a86ef987b054a206
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 7 (2022)
Implementation of inactivated polio vaccines (IPV) containing Sabin strains (sIPV) will further enable global polio eradication efforts by improving vaccine safety during use and containment during manufacturing. Moreover, sIPV-containing vaccines wi
Externí odkaz:
https://doaj.org/article/62ea5b6f2aeb4dde920e62169fbc236e
Autor:
Sakshi Bajoria, Kawaljit Kaur, Ozan S. Kumru, Greta Van Slyke, Jennifer Doering, Hayley Novak, Sergio A. Rodriguez Aponte, Neil C. Dalvie, Christopher A. Naranjo, Ryan S. Johnston, Judith Maxwell Silverman, Harry Kleanthous, J. Christopher Love, Nicholas J. Mantis, Sangeeta B. Joshi, David B. Volkin
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
Low-cost, refrigerator-stable COVID-19 vaccines will facilitate global access and improve vaccine coverage in low- and middle-income countries. To this end, subunit-based approaches targeting the receptor-binding domain (RBD) of SARS-CoV-2 Spike prot
Externí odkaz:
https://doaj.org/article/35022f23ff944bc2b948e4fb228bed37
Autor:
Ying Wan, Vineet Gupta, Christopher Bird, Swathi R. Pullagurla, Paul Fahey, Angus Forster, David B. Volkin, Sangeeta B. Joshi
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 8, Pp 2501-2516 (2021)
Measles (Me) and rubella (Ru) viral diseases are targeted for elimination by ensuring a high level of vaccination coverage worldwide. Less costly, more convenient MeRu vaccine delivery systems should improve global vaccine coverage, especially in low
Externí odkaz:
https://doaj.org/article/c27b8dab694543c991dd19f356648ed3